Breaking News, Financial News

Financial Report: Schering-Plough 2Q

Pharmaceutical sales were down 3% in the quarter to $3.6 billion, reflecting 7% operational growth and an unfavorable impact from foreign exchange of 10%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough 2Q 2Q Revenues: $4.6 billion (-6%) 2Q Earnings: $671 million (+45%) YTD Revenues: $9.0 billion (-6%) YTD Earnings: $1.5 billion (+90%) Comments: Pharmaceutical sales were down 3% in the quarter to $3.6 billion, reflecting 7% operational growth and an unfavorable impact from foreign exchange of 10%. Remicade sales were $565 million (+2%). Nasonex sales were up 3% to $321 million. Sales of Temodar were $256 million (+2%). Sales of Pegintron were down 6% to $215 milli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters